Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome
- Registration Number
- NCT02330692
- Lead Sponsor
- Yonsei University
- Brief Summary
Developing a molecular genetic test that can identify prognostic factors which can predict response to treatment, and to contribute to the establishment of future therapeutic strategies base on prognostic factors by undergoing peripheral blood and bone marrow examination of Myelodysplastic Syndrome (MDS) patients at diagnosis and relapse.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
-
MDS diagnosed by bone marrow aspiration and biopsy at Severance Hospital.
- Male and Female over 16 years of age. ③ Written consent of the patient to participate in the cohort ④ Deaths during the study period are waiver of consent
Exclusion Criteria
① Refusal or trouble understanding the written consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the number of patients with MDS to examine new prognostic factors 10 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular genetic prognostic factors in MDS are identified through peripheral blood and bone marrow analysis in NCT02330692?
How do novel biomarkers from NCT02330692 compare to IPSS-R in predicting treatment outcomes for MDS subtypes like RAEB or CMML?
Which genetic mutations or epigenetic alterations in MDS patients correlate with relapse risk as studied in Yonsei University's NCT02330692 cohort?
What adverse event profiles are associated with MDS therapies when stratified by prognostic factors identified in peripheral blood and bone marrow evaluations?
How might findings from NCT02330692 influence combination therapies or targeted approaches for high-risk MDS subpopulations?
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Korea, Republic of